Clindamycin

Clindamycin Phosphate · CLINDAMYCIN PHOSPHATE 150 mg/mL · Injection, Solution · Intramuscular; Intravenous · Henry Schein, Inc.

NDC 00404-9838-04 · 1 VIAL in 1 BAG / 4 mL in 1 VIAL · ANDA · View full market →

The short version

4 companies list this market (plus 3 repackagers, which add no supply) — a reasonable cushion if one runs into trouble. FDA lists this drug as in shortage right now (9 presentations or makers) — reason given: “discontinuation of the manufacture of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

ⓘ How this was built

Data sources

FDA NDC Directory (openFDA) — labelers active in the last 30 days, repackagers classified from DailyMed SPL establishment roles
CMS NADAC — latest price vs the price in effect ~12 months earlier
FDA drug shortages and enforcement reports (openFDA)
FDA inspection classifications; DrugDashboards fragility score and 90-day shortage model

Method

Each sentence is a template that fires only when its condition holds in the data shown lower on this page: maker counts are distinct FDA labelers listing this molecule and dosage form in the last 30 days minus classified repackagers; the price trend compares the newest NADAC with the last price in effect at least 9 months earlier; shortage and recall sentences restate FDA rows for this drug's presentations (Class I/II, trailing 12 months); the plant sentence needs a MANUFACTURE-role establishment with a drug-quality OAI in 24 months; the verdict restates the fragility band; the risk sentence appears only when the model's probability is at least 1.5× the typical market. Nothing here is inferred beyond those rules.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00009-0902-18) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built

Data sources

CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)

Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ

$0.6876per unit

middle half $0.6780–$0.7252 · 9 plans · Apr 1, 2026

Est. net of rebatesⓘ

≈ $0.6876

generic — rebates are minimal, so net ≈ gross

Coverage & restrictions

<1%of plans cover it

tier 1 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies a 25–40% brand range derived from MedPAC's program-wide aggregates to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

ⓘ How this was built

Data sources

CMS NADAC weekly files (data.medicaid.gov), December 2024 onward
CMS NADAC per-year archive files, 2013 – November 2024, averaged per month
CMS Federal Upper Limit file — weighted average manufacturer price (WAMP) of the generic group (dashed line)

Method

One line, two regimes: before December 2024 each point is the average of that month's archived NADAC rows for this NDC; from December 2024 each point is a row from the weekly file, which CMS publishes only when the price changes, so the line holds flat until the next change and is extended to today when the last row is under 6 months old. Since the December 2024 file CMS computes generic NADAC as a 3-month moving average, so recent generic moves are smoothed and lag the market. The dashed WAMP is the manufacturer-side average for the whole multiple-source group, not this NDC alone. To check a point: open the NADAC file for that date on data.medicaid.gov and find this NDC.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Medicare Part B (ASP)

ⓘ How this was built

Data sources

CMS Medicare Part B ASP quarterly pricing file and NDC–HCPCS crosswalk

Method

The payment limit CMS publishes for each HCPCS billing code this NDC maps to in the newest quarter's crosswalk. The limit is ASP+6% for most codes, WAC+3% for newly launched drugs, and ASP plus 8% of the reference product's ASP for some biosimilars; the 2% sequestration reduction is applied at claim level and is not reflected here. The unit is the code's billing unit, not the package. To check: open the ASP pricing file and crosswalk for the quarter shown on cms.gov.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Payment limit per 300 MG

$1.974

HCPCS J0736 · Inj, clindamycin phosp 300mg · Jul 1, 2026 quarter

Supply fragility

Not scored — fragility is computed for NDCs that have a NADAC price and a generic name.

Establishments on the label

Henry Schein, Inc.not a makerUnited States
relabel

Establishments this product's FDA label declares, with the role the label gives each (manufacture, API manufacture, pack, label, repack, analysis), located via FDA registration data. How we built this →

ⓘ How this was built

Data sources

DailyMed SPL labels (human prescription full release, monthly) — establishment DUNS and operations per label
FDA Drug Establishments Current Registration Site (DECRS) — DUNS to name and country
FDA Data Dashboard inspection classifications (Drug Quality Assurance)

Method

The label for this product's NDC-9 names each establishment and its operations; those DUNS numbers are matched to FDA's registration list for name and country. Only rows with a MANUFACTURE or API MANUFACTURE operation are places the drug is made; repack, relabel, pack, label and analysis rows are shown as what they are. The OAI badge means a drug-quality (GMP) inspection at that facility ended in Official Action Indicated within 24 months. Labels list plants, not volumes — a drug with two named plants may be made almost entirely at one. To check: open the label on DailyMed and its establishment section.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $38.65 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: ANDA090108
TE code: AP
Approval date: Sep 30, 2011
Patents / exclusivity: None on file

ⓘ How this was built

Data sources

FDA Orange Book data files — patent and exclusivity tables for application ANDA090108, edition retrieved 2026-08-24

Method

Rows are the Orange Book's patent and exclusivity listings for this NDA, de-duplicated across product numbers (the file repeats a listing for every strength). A listed patent is a claim the sponsor filed; it may cover a use rather than the molecule, may be challenged, and may be delisted — a listing is not proof a generic is blocked. Pediatric extensions appear as *PED rows. FDA blocks automated downloads of the Orange Book from cloud servers, so the edition can trail FDA's monthly release; the retrieval date above is the edition shown. To check: search the application number on FDA's Orange Book site.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Shortage history

ⓘ How this was built

Data sources

FDA drug shortages via openFDA (current file: Current, To Be Discontinued, and recently Resolved rows)
Internet Archive (Wayback) snapshots of FDA's shortage list since 2019, reconstructed into episodes
DrugDashboards Kaplan–Meier duration curves and conditional duration model

Method

Top rows are FDA's live listings whose package NDC is this product or another package of the same generic name and dosage form. openFDA drops resolved rows after about six months, so older episodes come from monthly Wayback snapshots of FDA's file, matched on the molecule with dosage-form words stripped (that matching can pull in other salts or forms of the same molecule — the presentation is shown so you can tell). 'Month N of a typical M' compares this episode's age with the Kaplan–Meier median for its form class (injectable, oral solid, other) over episodes since October 2019, open episodes censored; the resolution odds come from a model conditioned on the episode's age and reason. To check: FDA's drug shortage database, and web.archive.org for its history.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Planned discontinuation — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18)Jun 1, 2026
Planned discontinuation — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06)Jun 1, 2026
In shortage now — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)Mar 21, 2023
Demand increase for the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)Mar 21, 2023
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months
In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)Mar 21, 2023
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months
In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months
In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months
In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)Mar 21, 2023
Discontinuation of the manufacture of the drug
month 42 — 2× the typical 20-month injectable shortage · model puts 28% odds the market's longest-running episode resolves within 6 months

Archived episodes (FDA list history via Wayback, 2019+)

Planned discontinuation — Pfizer Inc., Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04) (listed as “Clindamycin Phosphate Injection”)Jun 1, 2026 → last seen Jul 20, 2026
Planned discontinuation — Pfizer Inc., Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06) (listed as “Clindamycin Phosphate Injection”)Jun 1, 2026 → last seen Jul 20, 2026
Planned discontinuation — Pfizer Inc., Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26) (listed as “Clindamycin Phosphate Injection”)Jun 1, 2026 → last seen Jul 20, 2026
Planned discontinuation — Pfizer Inc., Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02) (listed as “Clindamycin Phosphate Injection”)Jun 1, 2026 → last seen Jul 20, 2026
Planned discontinuation — Pfizer Inc., Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26) (listed as “Clindamycin Phosphate Injection”)Jun 1, 2026 → last seen Jul 20, 2026
Planned discontinuation — Pfizer Inc., Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18) (listed as “Clindamycin Phosphate Injection”)Jun 1, 2026 → last seen Jul 20, 2026
In shortage now — Pfizer Inc., Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04) (listed as “Clindamycin Phosphate Injection”)Mar 21, 2023 → last seen Jul 20, 2026
In shortage now — Baxter Healthcare, Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50) (listed as “Clindamycin Phosphate Injection”)Mar 21, 2023 → last seen Jul 20, 2026

Showing 8 of 30 archived episodes.

Recalls (this NDC)

ⓘ How this was built

Data sources

FDA drug enforcement reports via openFDA

Method

Enforcement reports whose product NDC list includes this exact package NDC, newest first, with FDA's classification (I = reasonable probability of serious harm, II = temporary or reversible harm, III = unlikely to cause harm) and the recall's current status. Reports for other packages of the same drug are not shown here; 275 of the last year's Class I/II reports carry no NDC at all and cannot be matched. To check: search the recall number on openFDA or FDA's enforcement reports.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

No enforcement reports list this package NDC.

Labelers of Clindamycin Phosphate (Injection, Solution)

7 labelers active in the last 30 days, of which 3 are repackagers; 0not seen for 30+ days. Keyed on FDA's generic-name string — other salts or forms of the molecule are separate rosters.

ⓘ How this was built

Data sources

FDA NDC Directory (openFDA), read daily since 2026-07-15 — labeler_name per package
DailyMed SPL establishment roles + name patterns → derived.labeler_kinds (repackager / manufacturer / unknown)

Method

One row per labeler that lists any package with this exact generic-name string and dosage form; strengths are combined. 'First seen' is the first daily snapshot that contained the labeler here (2026-07-15 for everything present at the start), 'last seen' the most recent; a labeler counts as active when seen in the last 30 days. Repackagers and relabelers are flagged when their own labels show only repack/relabel operations or their name matches a known repackager, and are excluded from every 'makers' count on this page. Listing is not volume: a labeler with a listed NDC may ship little or nothing. To check: search the generic name in FDA's NDC Directory and list the labelers.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Labeler	Strengths	First seen	Last seen
Baxter Healthcare Company	CLINDAMYCIN PHOSPHATE 300 mg/50mL; CLINDAMYCIN PHOSPHATE 600 mg/50mL; CLINDAMYCIN PHOSPHATE 900 mg/50mL	Jul 15, 2026	Sep 3, 2026
Medical Purchasing Solutions, LLCrepackager	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Sep 3, 2026
Pharmacia & Upjohn Company LLC	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Sep 3, 2026
Baxter Healthcare Corporation	CLINDAMYCIN PHOSPHATE 600 mg/50mL; CLINDAMYCIN PHOSPHATE 900 mg/50mL	Jul 15, 2026	Sep 2, 2026
ProPharma Distributionrepackager	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Sep 2, 2026
Sagent Pharmaceuticals	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Sep 2, 2026
Henry Schein, Inc.repackager	CLINDAMYCIN PHOSPHATE 150 mg/mL	Jul 15, 2026	Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 15, 2026.

Cite this page

DrugDashboards, "Clindamycin — NDC 00404-9838-04," retrieved September 4, 2026, https://drugdashboards.com/drug/00404983804.

Free to cite with attribution — see how the data is put together.